VideoHIVInternational Workshop on HIV Pediatrics 2020Safety, Pharmacokinetics And Acceptability Of The Abc/3tc/Lpv/R Granules (4-In-1) In Children Living With HIV (3-20kg) In Uganda: LOLIPOP Study - Juliet MwangaView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Safety, Pharmacokinetics, and Efficacy of Low-Dose E/C/F/TAF in Virologically Suppressed Children ≥2 Years Old Living with HIV - Eva NatukundaView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Pediatric Dolutegravir (DTG) Dosing Recommendations Derived from Combined P1093 and ODYSSEY Population Pharmacokinetic Analysis - Rajendra SinghView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Twenty-Four Week Safety, Tolerability and Efficacy of Dolutegravir Dispersible Tablets in Children 4 Weeks to <6 Years Old with HIV: Results from IMPAACT P1093 - Theodore RuelView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Q&A - Session 7: COVID-19 in PediatricsView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Clinical Illness Including MIS-C - Elizabeth WhittakerView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Susceptibility and Ability to Transmit - Lynne MofensonView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Session 6: Oral Abstract Session 5 - Prevention of HIV Mother-to-Child TransmissionView Video
VideoHIVInternational Workshop on HIV Pediatrics 2020Session 6: Oral Abstract Session 4 - COVID-19 in ChildrenView Video
